Ovoca Bio plc

LSE OVB.L

Ovoca Bio plc Net Income Margin for the year ending December 31, 2023

Ovoca Bio plc Net Income Margin is NA for the year ending December 31, 2023. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

LSE: OVB.L

Ovoca Bio plc

CEO	Mr. Timothy Rand McCutcheon
IPO Date	Jan. 4, 2000
Location	Ireland
Headquarters	17 Pembroke Street Upper
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Key trends

Past 5 years